Vibrato Medical

Vibrato Medical is an early-stage, pre-revenue medical device innovator targeting a significant unmet need in vascular disease. The company's core technology is a first-of-its-kind wearable therapeutic ultrasound device designed to noninvasively promote vasodilation and angiogenesis (new blood vessel growth) in patients with advanced PAD and CLI, potentially offering a limb-saving alternative to invasive revascularization procedures. Backed by NIH grant funding (R44HL156543) and led by an experienced CTO with a history of medical device development and exits, Vibrato is initiating its first clinical trials to demonstrate safety and efficacy. If successful, its home-use platform could disrupt the standard of care for millions of patients worldwide.

A novel, noninvasive, wearable therapeutic ultrasound device designed to promote vasodilation, collateral vessel growth, and angiogenesis (new blood vessel formation) to improve tissue perfusion. It is intended for chronic, home-based use with integrated patient compliance monitoring.

Vibrato's direct competitors are existing revascularization methods: surgical bypass and endovascular interventions (angioplasty, stents, atherectomy) offered by large medtech companies (e.g., Boston Scientific, Medtronic, Abbott). It also competes with pharmacologic therapies and wound care. Its key differentiation is noninvasiveness and wearability. Other noninvasive approaches (e.g., external counterpulsation, spinal cord stimulation) exist but are not widely adopted for CLI. Vibrato's technology, if proven, could create a new category of noninvasive vascular therapy.